Asthma Therapeutics Industry Set to Achieve $44.53 Billion Milestone by 2029 | Steady 7.7% CAGR

Get 30% off global market reports with code ONLINE30 and keep ahead of tariffs, macro trends, and worldwide economic developments.

What Is the Long-Term Growth Forecast for the Asthma Therapeutics Market Size 2025?
There has been significant growth in the market size of asthma therapeutics in recent times. The market will escalate from $30.63 billion in 2024 to $33.11 billion in 2025, boasting a compound annual growth rate (CAGR) of 8.1%. This previous progress is attributed to increased consciousness regarding management of asthma, a surge in the utilization of inhalers and nebulizers, a rise in allergic asthma cases due to pollution, higher government initiatives committed to respiratory health, and the expansion of healthcare infrastructure in developing economies.

What CAGR is Forecasted for the Asthma Therapeutics Market Through 2029?
In the forthcoming years, the asthma therapeutics market size is slated for substantial growth, projected to increase to $44.53 billion in 2029 with a compound annual growth rate (CAGR) of 7.7%. Factors contributing to this growth during the predicted period include an upswing in demand for biologics for asthma treatment, a heightened concentration on personalized medicine, expanding usage of digital inhalers and intelligent health devices, an increase in pediatric asthma cases, and stepped-up investment in R&D for new therapeutics. Key trends for the anticipated period comprise advancements in biologic therapies for severe asthma, cutting-edge inhaler technologies with digital tracking, formulation of personalized asthma treatment strategies, novelty in drug delivery systems, and incorporating artificial intelligence and wearable devices for asthma surveillance.

Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/asthma-therapeutics-global-market-report

What Are the Critical Factors Driving Asthma Therapeutics Market Development?
The rise in asthma cases is set to fuel the expansion of the asthma therapeutics market. Asthma is a chronic ailment that leads to inflammation and swelling of the airways, which subsequently narrows the passageways that transport air from the nose and mouth to the lungs. Asthma cases are on the rise due to an increase in pollutants that irritate the airways and elevate the chances of acquiring the disease. Asthma therapeutics play a significant role in managing asthma, controlling inflammation of the airways, reducing symptoms, and preventing asthma attacks. Medications for long-term control such as inhaled corticosteroids minimize chronic inflammation while quick-response medications like bronchodilators provide instant relief during asthma flare-ups. For example, Asthma + Lung UK, a charity based in England assisting people with lung conditions, reported in April 2024 that the number of deaths caused by asthma in England rose from 1,146 in 2021 to 1,236 in 2022. Consequently, the surging asthma cases are propelling the expansion of the asthma therapeutics market.

Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25702&type=smp

How Does the Asthma Therapeutics Market Break Down Across Major Segments?
The asthma therapeutics market covered in this report is segmented -

1) By Drug Class: Inhaled Corticosteroids (ICS), Long-Acting Beta Agonists (LABA), Leukotriene Receptor Antagonists (LTRA), Short-Acting Beta Agonists (SABA), Biologics, Combination Inhalers (ICS + LABA)
2) By Treatment Stage: Acute Treatment, Long-Term Control, Preventive Treatment, Maintenance Regimens, Rescue Medications
3) By Route Of administration: Oral, Inhaled, Intravenous, Subcutaneous
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Homecare, Specialty Clinics

Subsegments:
1) By Inhaled Corticosteroids (ICS): Fluticasone, Budesonide, Beclomethasone, Mometasone, Ciclesonide
2) By Long-Acting Beta Agonists (LABA): Salmeterol, Formoterol, Indacaterol, Olodaterol
3) By Leukotriene Receptor Antagonists (LTRA): Montelukast, Zafirlukast, Pranlukast
4) By Short-Acting Beta Agonists (SABA): Albuterol (Salbutamol), Levalbuterol, Terbutaline
5) By Biologics: Omalizumab, Mepolizumab, Benralizumab, Dupilumab, Reslizumab
6) By Combination Inhalers (ICS + LABA): Fluticasone + Salmeterol, Budesonide + Formoterol, Mometasone + Indacaterol, Beclomethasone + Formoterol

What Are the Major Trends Transforming the Asthma Therapeutics Industry?
Leading businesses in the asthma therapeutics arena are pioneering the creation of novel products, such as fixed-dose combination (FDC) medications, aimed at increasing treatment productivity and bolstering patient compliance. An FDC medication is a single-dose pharmaceutical which combines two or more active ingredients targeted at treating a specific disease. For example, Glenmark Pharmaceuticals Limited, a company founded in India, introduced a groundbreaking FDC drug, Indacaterol plus Mometasone, designed specifically for asthma treatment in June 2022. Indacaterol, a long-acting beta-agonist (LABA), works to alleviate tension in the airway muscles and Mometasone, an inhaled corticosteroid (ICS), functions to curb lung inflammation. This particular FDC format is intended to provide better symptom control and streamline the treatment process with once-daily doses, aiming to enhance adherence to treatment regimes among patients with moderate to severe asthma.

Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25702&type=smp

Which Players Are Driving Innovation in the Asthma Therapeutics Market?
Major companies operating in the asthma therapeutics market are Roche Holding AG, Merck & Co Inc., Pfizer Inc., AstraZeneca plc, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Sun Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A., Cipla Limited, Mundipharma International Limited, ALK-Abello, Mylan N.V., Whanin Pharmaceutical, Mitsubishi Tanabe Pharma, Allergan plc.

Which Regions Are Driving Global Asthma Therapeutics Market Expansion?
North America was the largest region in the asthma therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

#Reach Out to Us#

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.